goal
vaccin
initi
strong
immun
respons
lead
develop
last
protect
immun
vaccin
pathogen
common
approach
develop
vaccin
cancer
cell
host
protein
small
molecul
drug
develop
purpos
articl
focu
primarili
use
platform
develop
vaccin
infecti
diseas
immun
system
compos
innat
nonspecif
adapt
specif
branch
pathogen
breach
host
physic
barrier
mucos
surfac
skin
cell
innat
immun
system
recogn
gener
characterist
pathogen
initi
molecular
pattern
pamp
molecul
common
mani
pathogen
lipopolysaccharid
lp
found
cell
wall
mani
bacteri
speci
rna
unmethyl
cpg
motif
normal
associ
viru
infect
pamp
recogn
receptor
tlr
receptor
prr
present
surfac
host
intrins
properti
multival
display
highli
order
structur
present
mani
pathogen
also
facilit
recognit
pamp
result
increas
immunogen
pamp
stimul
antigen
uptak
antigen
present
cell
subsequ
present
antigen
cell
adapt
immun
respons
furthermor
initi
respons
polymorphonuclear
pmn
leukocyt
granulocyt
natur
killer
nk
cell
induc
releas
cytokin
promot
elimin
pathogen
adapt
immun
respons
take
longer
develop
order
day
adapt
respons
requir
recognit
pathogen
host
lymphocyt
interact
receptor
uniqu
lymphocyt
enorm
repertoir
possibl
receptor
combin
allow
recognit
almost
antigen
antigen
deliv
adapt
immun
system
stimul
prolifer
effector
cell
cell
begin
elimin
pathogen
adapt
respons
also
basi
immunolog
memori
import
ensur
fast
strong
respons
infecti
pathogen
encount
memori
lymphocyt
form
subsequ
initi
rapid
immedi
immun
respons
upon
reintroduct
pathogen
vaccin
capit
immun
memori
stimul
format
memori
cell
specif
antibodi
pathogen
avail
rapidli
recogn
natur
pathogen
futur
exposur
ideal
vaccin
util
process
introduc
immun
system
specif
pathogen
allow
format
memori
cell
futur
recognit
yet
avoid
symptom
ill
transmiss
pathogen
individu
virus
continu
evolv
attribut
allow
surviv
hostil
environ
host
evolv
strategi
recogn
reliev
pathogen
take
advantag
natur
strategi
recognit
develop
vaccin
classic
approach
vaccin
develop
involv
chemic
inactiv
viru
particl
infect
tissu
term
kill
vaccin
attenu
virul
passag
tissu
cultur
anim
host
term
vaccin
immun
portion
pathogen
induc
specif
immun
respons
term
subunit
vaccin
gener
vaccin
virus
delic
balanc
protect
safeti
first
reach
use
whole
viru
inactiv
kill
recent
understand
immun
system
activ
improv
becom
appar
even
small
immunogen
peptid
deriv
pathogen
potenti
induc
protect
current
larg
number
success
vaccin
base
whole
virus
whether
inactiv
first
vaccin
develop
smallpox
edward
jenner
also
involv
administr
less
pathogen
cowpox
vaccinia
method
immun
vaccinia
crude
imprecis
mechan
immun
protect
well
understood
potenti
ill
high
next
centuri
variou
vaccin
rang
infecti
primarili
bacteri
agent
cholera
tetanu
bubon
plagu
develop
use
human
major
advanc
toward
develop
modern
vaccin
abil
grow
produc
virus
laboratori
cell
cultur
allow
better
character
standard
first
licens
vaccin
produc
cell
cultur
inject
dose
kill
polioviru
develop
jona
salk
announc
american
public
vaccin
quickli
follow
suit
tremend
success
reduc
morbid
mortal
worldwid
includ
measl
mump
rubella
influenza
inactiv
hepat
spite
success
polioviru
vaccin
intrins
disadvantag
involv
use
whole
viru
particl
viral
vaccin
rel
unstabl
difficult
deliv
potenti
genet
revers
attenu
strain
virul
form
alway
concern
administr
kill
vaccin
negat
particular
problem
immun
respons
weaker
regimen
dose
gener
requir
increas
expens
reduc
vaccin
coverag
popul
addit
complet
inactiv
vaccin
viru
must
assur
prevent
infect
subunit
vaccin
prime
immun
respons
deliveri
subset
immunogen
viral
protein
often
portion
viru
capsid
figur
potenti
replic
subunit
vaccin
potenti
much
safer
often
less
immunogen
express
purifi
absenc
viral
compon
advanc
area
involv
natur
abil
mani
type
viral
capsid
subunit
particl
vlp
allow
better
mimic
whole
viru
particl
result
improv
effect
vaccin
figur
advanc
util
vlp
platform
attach
display
foreign
epitop
nonstructur
viral
protein
nonvir
protein
strategi
coupl
deliveri
chosen
antigen
abil
vlp
induc
strong
immun
respons
eas
vlp
often
made
variou
antigen
attach
make
everi
potenti
platform
promis
onset
howev
applic
platform
complex
system
involv
uniqu
challeng
problem
may
limit
progress
clinic
use
approach
discuss
well
summar
tabl
two
success
vaccin
licens
approv
use
human
first
commerci
hepat
b
viru
hbv
vaccin
hbv
infect
transmit
blood
sexual
contact
major
caus
hepat
hepatocellular
carcinoma
affect
approxim
million
peopl
worldwid
initi
vaccin
formul
empti
particl
small
surfac
antigen
hbsag
natur
made
infect
hepat
b
present
blood
obtain
infect
individu
purifi
limit
quantiti
antigen
produc
method
led
investig
potenti
make
particl
recombin
protein
express
express
system
yeast
baculoviru
mammalian
cell
often
util
cultur
produc
larg
amount
protein
vitro
case
hbv
vector
prepar
carri
cdna
sequenc
hbsag
surfac
antigen
protein
express
recombin
yeast
cell
cultur
vlp
form
studi
confirm
immunogen
particl
human
inclus
surfac
protein
protein
present
nativ
hbv
envelop
lower
level
hbsag
allow
immun
respons
small
percentag
patient
respond
vlp
hbsag
case
better
mimic
authent
virion
surfac
result
broaden
effect
commerci
success
vaccin
licens
safe
effect
exampl
vaccin
compar
effect
vaccin
facilit
explor
complex
issu
administr
poorer
countri
hbv
epidem
applic
current
vaccin
limit
due
cost
recent
advanc
test
possibl
oral
deliveri
hbv
particl
produc
transgen
second
commerci
avail
vaccin
human
papillomaviru
hpv
effect
hpv
vaccin
particular
interest
link
hpv
infect
particularli
genotyp
cervic
intraepitheli
neoplasia
cervic
cancer
hpv
capsid
consist
two
protein
express
major
capsid
protein
either
alon
combin
result
product
nm
vlp
induc
neutral
antisera
immun
human
femal
demonstr
hpv
vaccin
protect
infect
hpv
also
reduc
prevent
entir
develop
intraepitheli
neoplasia
control
patient
receiv
placebo
subset
infect
hpv
develop
cervic
intraepitheli
neoplasia
current
hpv
vaccin
show
great
promis
almost
complet
protect
hpv
type
deriv
even
absenc
adjuv
adjuv
achiev
partial
protect
phylogenet
relat
vlp
vaccin
consid
breakthrough
prevent
cervic
cancer
interest
observ
impact
vaccin
cervic
cancer
rate
futur
sinc
also
recent
associ
oropharyng
vaccin
may
impact
futur
rate
diseas
well
hbv
vaccin
product
character
vlp
expens
result
higher
vaccin
cost
approach
reduc
cost
express
protein
pentamer
capsomer
combin
viral
protein
vaccin
variou
stage
vlp
hepat
e
viru
hev
viru
thought
caus
acut
sever
liver
diseas
individu
shown
immunogen
protect
macaqu
pass
phase
clinic
experiment
protein
requir
hev
vlp
format
facilit
understand
format
howev
circumst
specif
diseas
hamper
test
protect
efficaci
clinic
attack
rate
hev
low
sporad
requir
larg
number
vaccin
control
individu
achiev
interpret
result
vlp
norwalk
viru
highli
infecti
viru
major
caus
gastrointestin
ill
test
adult
stride
toward
oral
norwalk
viru
vaccin
produc
tobacco
leav
potato
tuber
success
oral
immun
mice
result
product
serum
mucos
addit
vlp
vaccin
found
much
success
prevent
viral
nervou
necrosi
diseas
envelop
vlp
virus
influenza
hiv
hcv
similarli
immunogen
consist
assembl
particl
contain
surfac
compon
viru
embed
plasma
membran
vlp
express
baculoviru
compos
influenza
hemagglutinin
ha
neuraminidas
na
matrix
structur
protein
induc
product
specif
antibodi
rout
entri
presenc
cytokin
adjuv
alter
immun
respons
afford
differ
level
addit
although
individu
influenza
protein
capabl
induc
protect
immun
respons
use
recombin
reveal
problem
may
underli
problem
mani
vaccin
use
recombin
protein
recombin
ha
protein
poorli
immunogen
peopl
perhap
due
differ
modif
abil
hiv
consist
effect
evad
immun
system
time
make
develop
effect
vaccin
hiv
particularli
difficult
surfac
vlp
vaccin
may
disadvantag
compar
current
vaccin
strategi
vlp
similar
viral
structur
elicit
protect
respons
infect
individu
howev
modif
hiv
vlp
could
advanc
strategi
addit
mucos
administr
particl
elicit
strong
neutral
antibodi
ctl
effici
induct
broadli
neutral
antibodi
thought
essenti
compon
induc
protect
nevertheless
antibodi
identifi
small
subset
patient
yet
possibl
induc
antibodi
experiment
one
signific
challeng
difficulti
produc
antigen
structur
similar
found
intact
hiv
particl
product
hiv
vlp
confront
problem
attempt
mimick
intact
hiv
particl
contain
envelop
protein
associ
viral
gag
protein
focu
recent
research
conserv
epitop
envelop
nevertheless
challeng
effici
hiv
vaccin
requir
manipul
differ
vlp
express
system
avail
vaccin
envelop
virus
potenti
ultim
use
human
progress
made
develop
vlp
hepat
c
viru
hcv
filovirus
ebola
viru
ebov
marburg
viru
marv
sar
chikungunya
mani
case
assembl
stabil
vlp
limit
size
potenti
insert
small
peptid
aa
often
suffici
initi
antibodi
product
exampl
addit
small
peptid
immunogen
region
vlp
result
rel
strong
respons
howev
although
hbv
core
antigen
hbcag
shown
strongli
immunogen
green
fluoresc
protein
gfp
fuse
core
protein
introduct
result
robust
humor
immun
respons
nativ
gfp
rabbit
mainten
favor
properti
hbcag
addit
larg
protein
remain
antigen
region
hiv
envelop
protein
link
hbsag
produc
particl
morpholog
similar
hbcag
exhibit
antigen
immunogen
characterist
hbv
short
aa
yet
highli
conserv
region
display
particl
elicit
high
titer
antibodi
mice
howev
fail
neutral
hiv
vitro
epitop
success
neutral
antibodi
product
present
influenza
vaccin
platform
thu
molecular
context
seem
import
consid
abil
elicit
protect
respons
howev
correct
process
particl
recognit
hiv
epitop
particl
impli
hbv
peptid
particl
epitop
elicit
similar
epitop
found
vari
level
success
display
hbv
platform
invari
extracellular
domain
influenza
fuse
hbc
administ
intraperiton
intranas
gave
protect
attach
epitop
foot
mouth
diseas
viru
fmdv
hbcag
vlp
provid
immunogen
stronger
peptid
alon
approach
fmdv
particl
nucleocapsid
puumala
hantaviru
hbc
provid
protect
immun
parasit
infect
also
stem
use
vaccin
circumsporozoit
cs
protein
malaria
express
hbc
protein
prove
highli
immunogen
mice
monkey
first
phase
trial
particl
thu
hbv
vlp
proven
product
platform
attach
epitop
potenti
use
vaccin
hbv
infect
elicit
strong
humor
respons
direct
singl
immunodomin
epitop
human
expect
insert
epitop
elicit
much
better
respons
c
thorough
investig
effect
posititon
immunogen
studi
insert
epitop
hbv
envelop
protein
amino
terminu
amino
terminu
linker
truncat
carboxi
terminu
intern
site
hbcag
effect
intern
site
result
high
antibodi
respons
weakest
immun
respons
amino
terminu
epitop
surfac
sinc
hpv
vaccin
approv
use
human
recent
studi
vlp
platform
vaccin
limit
chimer
hpv
vlp
made
progress
hiv
vaccin
although
administr
chimera
epitop
hiv
show
signific
protect
macaqu
show
protect
partial
protect
afford
plenti
opportun
test
locat
insert
affect
immunogen
foreign
peptid
hbc
epitop
introduc
variou
posit
hpv
vlp
order
assess
compar
differ
posit
although
insert
sometim
reduc
immunogen
chimera
form
particl
induc
neutral
antibodi
develop
hpv
vlp
platform
still
earli
stage
futur
success
particl
uncertain
highli
promis
explor
limit
increas
size
insert
epitop
tether
protein
extern
portion
like
allow
effici
format
immunogen
chimer
cpmv
extens
studi
vaccin
cpmv
comoviru
picornaviru
superfamili
form
nm
icosahedr
particl
compos
two
capsid
protein
term
larg
l
small
cpmv
promis
plant
viru
epitop
display
multipl
reason
larg
amount
icosahedr
cpmv
vlp
produc
natur
host
vigna
unguiculata
cowpea
underscor
potenti
manufactur
cpmv
particl
also
taken
number
differ
cell
type
vitro
vivo
follow
parenter
oral
particl
also
found
peyer
lymphoid
tissu
oral
administr
underscor
potenti
possibl
oral
heterolog
peptid
display
cpmv
produc
strong
antibodi
respons
administ
parenter
mucos
rout
result
mucos
administr
product
iga
antibodi
indic
potenti
protect
system
mucos
sever
expos
loop
capsid
surfac
particularli
one
compos
amino
acid
capsid
subunit
particular
interest
regard
develop
cpmv
vaccin
cpmv
particl
genet
modifi
includ
epitop
mink
enter
viru
mev
canin
parvoviru
cpv
mink
immun
mev
cpmv
particl
protect
viral
dog
immun
cpv
cpmv
particl
protect
lethal
challeng
epitop
protein
also
insert
cpmv
capsid
result
product
neutral
antibodi
suggest
potenti
applic
hiv
cpmv
nanoparticl
extens
studi
applic
bacteri
vaccin
well
administr
cpmv
particl
peptid
pseudomona
aeruginosa
outer
membran
om
protein
f
provid
pathogen
specif
antibodi
protect
express
om
epitop
tandem
protein
f
peptid
cpmv
particl
shown
site
peptid
express
influenc
immun
administr
cpmv
particl
truncat
domain
staphylococcu
aureu
induc
neutrophil
activ
macrophag
phagocytosi
vitro
provid
protect
endocard
vivo
cpmv
platform
provid
anoth
exampl
posit
insert
epitop
influenc
effici
protect
relationship
structur
epitop
insert
site
cpmv
immunogen
investig
display
epitop
human
rhinoviru
differ
posit
cpmv
capsid
case
demonstr
epitop
present
close
loop
result
polyclon
antisera
much
greater
capac
bind
intact
human
rhinoviru
one
drawback
toward
use
cpmv
vlp
frequent
proteolyt
cleavag
insert
epitop
result
loss
epitop
andor
destabil
heterogen
recent
advanc
toward
gener
noninfecti
vlp
use
agrobacterium
heterolog
express
plant
may
solv
problem
retain
possibl
tobacco
mosaic
viru
first
plant
viru
casid
genet
modifi
contain
foreign
epitop
tmv
rna
viru
infect
tobacco
plant
solanacea
famili
nm
capsid
made
monom
surround
genom
rna
provid
ideal
platform
vaccin
infect
anim
larg
quantiti
easili
obtain
particl
epitop
murin
hepat
viru
fmdv
success
provid
protect
infecti
particl
mice
guinea
pig
tmv
particl
also
use
platform
bacteri
epitop
includ
outer
membran
protein
f
pseudomona
aeruginosa
formul
elicit
protect
challeng
administ
tmv
may
effici
platform
epitop
display
highli
order
antigen
array
requir
number
potenti
epitop
per
particl
densiti
space
much
higher
icosahedr
arrang
cucumb
mosaic
viru
cmv
wide
host
rang
genom
linear
rna
nm
icosahedr
capsid
made
copi
singl
capsid
protein
cmv
particl
use
present
epitop
particl
epitop
success
elicit
pathogen
specif
respons
rabbit
hcv
patient
signific
releas
alfalfa
mosaic
viru
almv
four
particl
type
bacilliform
spheroid
made
coat
protein
viru
infect
plant
speci
famili
antigen
eptid
respiratori
syncyti
viru
g
protein
express
capsid
almv
specif
antibodi
produc
vitro
human
dendrit
cell
vivo
nonhuman
potato
viru
x
pvx
flexuou
rod
shape
type
member
potexviru
group
capsid
made
ident
coat
protein
subunit
pvx
particl
util
attach
epitop
even
yield
neutral
antibodi
papaya
mosaic
viru
papmv
form
nm
particl
immunogen
depend
multimer
papmv
coat
protein
interestingli
papmv
demonstr
efficaci
platform
use
induc
respons
process
typic
ineffici
use
nonrepl
vaccin
platform
nevertheless
immun
papmv
display
mhc
class
epitop
peptid
deriv
lymphocyt
choriomening
viru
lcmv
express
papmv
surfac
abl
protect
vaccin
mice
subsequ
challeng
similar
result
observ
parvoviru
vlp
display
howev
vlp
platform
effici
induc
class
ctl
respons
clear
vlp
result
effici
epitop
class
may
due
differ
rout
endocytosi
vlp
cell
govern
access
antigen
present
pathway
bacteriophag
present
yet
anoth
platform
deliveri
vaccin
anim
bacteriophag
rna
viru
infect
escherichia
coli
belong
rna
phage
famili
levivirida
nm
icosahedr
capsid
compos
copi
singl
coat
protein
display
antigen
particl
expand
technolog
area
diseas
besid
infect
immun
particl
coupl
nicotin
succeed
block
entri
nicotin
brain
antibodi
produc
sequest
molecul
blood
immun
smoker
excit
advanc
treatment
smoke
cessat
particl
current
phase
ii
clinic
anoth
bacteriophag
util
attach
display
viral
structur
similar
sequenc
determin
entir
cdna
copi
replicas
demonstr
region
homolog
coat
protein
show
sequenc
peptid
loop
hiv
insert
coat
protein
particl
shown
immunogen
anoth
bacteriophag
use
primarili
develop
vaccin
parasit
infect
filament
bacteriophag
made
copi
major
coat
protein
cap
five
copi
minor
coat
protein
recent
regimen
anticysticercosi
tripeptid
vaccin
pig
reduc
incid
infect
taenia
solium
parasit
infect
primarili
infect
human
pig
mexico
latin
american
countri
character
headach
seizur
infect
local
nervou
potenti
vaccin
candid
also
identifi
schistosoma
japonicum
infect
infect
human
wild
mammal
chronic
ill
damag
intern
effect
vaccin
import
case
littl
natur
immun
reinfect
rna
bacteriophag
investig
new
platform
heterolog
display
mani
antigen
vlp
form
copi
coat
protein
allow
fusion
epitop
fusion
gonadotropin
releas
hormon
gnrh
epitop
success
induc
antibodi
fusion
extracellular
domain
influenza
protein
elicit
protect
immun
mice
peptid
salmonella
typhi
nef
other
also
attach
platform
result
immun
bacteriophag
offer
ideal
bind
platform
antigen
hoc
soc
protein
accessori
structur
protein
outer
surfac
particl
provid
littl
stabil
hoc
particular
highli
four
domain
hoc
molecul
site
exposur
epitop
immun
system
ideal
particular
linker
region
domain
domain
system
discuss
although
abil
act
adjuv
may
reduc
nonanim
virus
also
potenti
use
platform
anim
vaccin
insect
viru
flock
hous
viru
fhv
wide
use
antigen
display
attach
deliveri
anim
figur
fhv
member
insect
viru
famili
nodavirida
cross
kingdom
barrier
also
replic
plant
neonat
mice
icosahedr
capsid
compos
subunit
coat
protein
sever
surfac
expos
loop
promis
site
insert
foreign
epitop
insert
hbv
hcv
epitop
variou
area
fhv
capsid
studi
compar
mani
highli
specif
reactiv
area
identifi
test
guinea
pig
hepat
b
c
patient
confirm
potenti
vaccin
hbv
fhv
particl
display
hiv
epitop
also
test
wherebi
neutral
domain
loop
insert
fhv
capsid
particl
initi
strong
immun
respons
guinea
case
extrem
difficult
elicit
effect
antibodi
respons
use
epitop
display
loop
carrier
protein
environ
differ
nativ
seldom
mimick
normal
conform
epitop
constraint
may
requir
whole
larg
protein
domain
conjug
vlp
surfac
larg
region
gener
fold
independ
allow
nativ
comform
import
immunogen
epitop
potenti
investig
fhv
hbv
system
recent
studi
show
addit
small
epitop
fhv
surfac
loop
amino
acid
could
accommod
larger
insert
sever
hundr
amino
acid
confirm
electron
figur
b
capit
featur
fhv
particl
display
larg
protein
insert
develop
potenti
function
antitoxin
vaccin
bacillu
anthraci
caus
agent
anthrax
two
enzymat
subunit
ab
type
toxin
b
anthraci
respons
toxic
effect
deliv
cell
bind
b
subunit
term
protect
antigen
pa
bind
receptor
adenyl
cyclas
edema
factor
ef
rais
intracellular
cyclic
adenosin
monophosph
level
zinc
proteas
lethal
factor
lf
cleav
protein
kinas
pa
bind
cleav
form
heptam
bind
ef
lf
form
edema
toxin
lethal
toxin
respect
fhv
particl
genet
engin
display
domain
anthrax
receptor
posit
bind
domain
deem
function
abil
bind
pa
inhibit
receptor
bind
intox
vitro
vivo
sinc
could
bind
pa
particl
test
multival
scaffold
display
antigen
pa
protein
follow
immun
complex
strong
antibodi
respons
along
protect
lethal
toxin
challeng
rat
confirm
abil
treatment
interestingli
increas
antibodi
respons
protect
observ
follow
immun
multival
compar
monomer
pa
alon
figur
e
f
addit
protect
respons
observ
singl
immun
without
addit
adjuv
result
confirm
idea
multival
antigen
present
facilit
effect
antibodi
respons
use
fhv
platform
display
larg
antigen
current
investig
hbv
also
use
platform
display
larg
antigen
hbv
also
use
display
larger
portion
dengu
viru
antigen
amino
acid
portion
dengu
viru
envelop
protein
type
effect
prime
protect
immun
respons
larg
portion
express
fusion
protein
hbsag
yeast
result
vlp
purifi
vlp
shown
function
bival
immunogen
hoc
soc
molecul
bacteriophag
ideal
candid
allow
attach
larg
antigen
protein
integr
capsid
assembl
bind
hoc
protein
fusion
hoc
either
pa
lf
ef
shown
bind
induc
immun
respons
individu
antigen
prove
concept
scaffold
could
use
display
multipl
antigen
simultan
consist
fhv
studi
respons
multimer
pa
higher
monomer
assembl
protein
phage
cleav
anthrax
protect
antigen
heptam
attach
serv
scaffold
bind
lf
figur
togeth
result
indic
vlp
scaffold
excel
potenti
display
antigen
complex
structur
combin
antigen
sinc
larger
complex
immunogen
mani
case
similar
natur
antigen
may
system
immun
larger
antigen
protein
particularli
fruit
vaccin
design
success
attach
antigen
foreign
particl
explor
attach
purpos
treat
diseas
attempt
antibodi
form
follow
administr
often
serv
competit
inhibitor
fight
diseas
often
intrins
problem
involv
administ
peptid
alon
gener
difficult
break
immunolog
toler
self
protein
peptid
typic
immunogen
attach
vlp
often
produc
heighten
immun
respons
addit
foreign
protein
multival
display
potenti
break
toler
varieti
vlp
use
display
includ
hbv
fhv
hpv
one
potenti
therapeut
avenu
prevent
hiv
infect
product
autoantibodi
hiv
cellular
receptor
indirect
rout
vaccin
avoid
problem
constant
mutat
viral
antigen
peptid
attach
hpv
vlp
administ
mice
particl
initi
product
autoantibodi
inhibit
bind
ligand
block
infect
indic
cell
line
express
use
similar
strategi
induct
antibodi
product
iga
antibodi
mucos
site
follow
administr
aerosol
pulmonari
formul
vaccin
confirm
potenti
focus
attack
hiv
first
line
contact
mucosa
human
indirect
rout
target
address
use
fhv
platform
well
insert
peptid
fhv
follow
administr
result
reduc
cell
human
furthermor
peptid
loop
coreceptor
hiv
insert
coat
protein
particl
shown
potent
potenti
riski
induc
hiv
may
one
exampl
risk
warrant
sinc
strategi
vaccin
develop
hiv
infect
success
alzheim
diseas
neurodegen
diseas
result
accumul
peptid
neurofibillari
tangl
loss
neuron
lead
dementia
one
therapeut
strategi
use
vaccin
elimin
accumul
plaqu
brain
hope
preserv
neuron
attach
peptid
papillomaviru
vlp
capsid
induc
high
level
specif
antibodi
inhibit
effect
assembl
peptid
neurotox
peptid
vitro
deposit
also
reduc
immun
mous
model
alzheim
howev
clinic
trial
anoth
vaccin
formul
peptid
result
develop
enceph
therefor
remain
determin
vaccin
effect
similar
sinc
research
come
better
understand
requir
gener
effect
vaccin
goal
synthet
mimic
vnp
becom
attain
principl
synthet
particl
might
even
safer
easier
produc
vlp
properti
immunogen
elimin
vivo
favor
nevertheless
progress
made
toward
synthet
nanoparticl
vaccin
exampl
follow
biodegrad
biocompat
microparticl
util
oral
immun
induct
local
system
immun
respons
poli
plg
biodegrad
materi
manipul
biodegrad
possibl
chang
polym
composit
molecular
weight
oral
intragastr
administr
microparticl
result
immun
respons
antigen
trap
insid
particl
includ
peptid
bacteri
toxoid
bacteri
although
plg
microspher
studi
extens
carrier
bacteri
vaccin
exampl
viral
vaccin
platform
show
particular
promis
certifi
us
food
drug
administr
prepar
deliveri
system
liposom
made
phospholipid
bilay
often
cholesterol
includ
stabil
artifici
prepar
empti
liposom
challeng
howev
success
incorpor
antigen
present
addit
liposom
often
elicit
strong
immun
respons
necessit
use
adjuv
although
continu
slow
steadi
increas
formul
perform
well
experiment
anim
ever
enter
expens
clinic
trial
product
continu
perform
expect
iscom
roughli
nm
spheric
micel
compos
saponin
mixtur
quil
strong
adjuv
cholesterol
licens
use
hors
made
progress
rotaviru
spite
advanc
iscom
perform
similarli
liposom
therefor
limit
progress
nanoemuls
ne
vaccin
promis
noninflammatori
mucos
adjuv
use
nasal
vaccin
platform
requir
mani
current
vaccin
administ
inject
limit
broad
use
vaccin
worldwid
use
deliveri
platform
would
facilit
vaccin
develop
synthet
platform
excit
area
develop
learn
biolog
base
particl
effici
prime
protect
immun
respons
principl
like
translat
synthet
system
well
vaccin
share
problem
encount
vaccin
even
effici
cellular
humor
immun
respons
reli
longev
host
respons
addit
use
vlp
vaccin
immunocompromis
patient
encount
problem
effici
immun
respons
vaccin
approach
vlp
shown
promis
mani
subunit
vaccin
conform
authent
safer
due
lack
genet
sucess
hbv
particl
human
spur
intens
interest
develop
vlp
vnp
kind
particularli
engin
complex
structur
antigen
multipl
antigen
deliveri
system
sever
obstacl
uniqu
vaccin
consid
bring
particl
research
tool
use
patient
popul
one
concern
potenti
toxic
nanoparticl
human
bodi
slow
speed
biodegrad
materi
abil
span
biolog
membran
high
surfac
area
reactiv
may
lead
unaccept
toxic
affect
human
anoth
consider
complex
clinic
trial
vaccin
usual
administ
healthi
human
infant
adult
trial
nonhuman
primat
often
need
demonstr
safeti
toler
vaccin
addit
preclin
studi
involv
immun
immedi
follow
challeng
test
protect
human
trial
requir
wait
outbreak
occur
protect
analyz
nevertheless
benefit
human
health
histor
outweigh
drawback
vaccin
consid
one
effect
mean
improv
global
health
worldwid
thu
warrant
sustain
effort
continu
improv
safeti
efficaci
